



HEALTH HOLDING
HAFER ALBATIN HEALTH
CLUSTER
MATERNITY AND
CHILDREN HOSPITAL

| | | | |
|--------------------------|---|-------------------------|---------------|
| Department: | Laboratory and Blood Bank (Chemistry) | | |
| Document: | Internal Policy and Procedure | | |
| Title: | Analysis of Creatine Kinase Level | | |
| Applies To: | All Laboratory Staff | | |
| Preparation Date: | January 06, 2025 | Index No: | LB-IPP-158 |
| Approval Date: | January 20, 2025 | Version : | 2 |
| Effective Date: | February 20, 2025 | Replacement No.: | LB-IPP-158(1) |
| Review Date: | February 20, 2028 | No. of Pages: | 04 |

1. PURPOSE:

- 1.1 The purpose of this policy & procedure is to provide all information related to the analysis of creatine kinase level in blood (serum/plasma) on DimensionEXL200 ,Synchron DXC700 and Atelica CI.

2. DEFINITONS:

- 2.1 Creatine kinase is an enzyme catalysing the transfer of a phosphate group from phosphocreatine to ATP.

3. POLICY:

- 3.1 It is a test used to determine the level of total creatine kinase in the blood.
- 3.2 The CK enzyme is a dimer composed of subunits derived from either muscle (M) or brain (B). Elevated CK serum levels are found in skeletal muscle disease, particularly muscular dystrophy. Serum CK activity is also increased after cerebral ischemia, acute cerebrovascular disease, and head injury.

4. PROCEDURE:

4.1 Specimen:

- 4.1.1 Type:
- 4.1.1.1 Serum, or plasma
- 4.1.2 Tube Type:
- 4.1.2.1 Gel tube, Plain tube; Li-Heparin
- 4.1.3 Amount Required:
- 4.1.3.1 2.0 to 3.0 ml
- 4.1.4 Delivery Arrangements:
- 4.1.4.1 Sample to be delivered to the lab as soon as possible.
- 4.1.5 If the sample is serum should be ensuring complete clot formation before centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.
- 4.1.6 Temperature Restrictions:
- 4.1.6.1 At room temperature
- 4.1.7 Unacceptable Specimen:
- 4.1.7.1 See sample rejection criteria policy.
- 4.1.8 Specimen Retention:
- 4.1.8.1 Period of retention: up to one week after separation of the sample.
- 4.1.8.2 Storage condition: store at 2-8 °C
- 4.1.9 Safety Precaution:
- Treat all samples material as infectious and handled in accordance with the OHSA standard on blood borne pathogens.

4.2 Principle:

| |
|---|
| Creatine phosphate + ADP ---- CK ----- creatine + ATP |
| ATP + D-glucos----- HK----- ADP + G6P |
| G6P + (NADP+) -----G6PDH----- . D-6-phosphogluconate + NADPH +(H+) |

4.2.1 The rate of the NADPH formation is directly proportional to the catalytic CK activity in the sample is measured biochromatically at 340 and 540 nm.

4.3 Method:

4.3.1 See policy of loading sample on machine (Ref: Operative Manuals' of DimensionEXL200 ,Synchron DXC700 and Atelica CI

4.4 Calculation:

4.4.1 Instrument system automatically calculates the Analytic activity and gives results in the form of printout.

4.5 Format:

4.5.1 Numeric

4.6 Status:

4.6.1 Stat and Routine

4.7 Reference ranges:

4.7.1 Serum/plasma

4.7.1.1 Males: 39-208 U/L

4.7.1.1 Females :26-192 U/L

4.8 Dilution information:

4.8.1 Specimens with values exceeding the linearity range are flagged and may be diluted with automatic dilution either automated or manual dilution. Manual Dilution should be performed as follows:

4.8.1.1 Use saline (0.85% to 0.90%) to dilute the sample.

4.8.1.2 The operator must enter the dilution factor in the patient order screen. The system dilution factor to automatically correct the concentration by multiplying the result by factor.

4.8.1.3 If the operator does not enter the dilution factor, the result must be multiplied appropriate dilution factor before reporting the result.

4.8.1.4 If a diluted sample result generates a Linear Low (LL) result error code. Do result. Prepare an appropriate dilution/concentration and rerun.

4.9 Linearity:

4.9.1 is linear up to 1000 U/L

4.10 Limit of Detection:

4.10.1 The Limit of Detection is 7 U/L

5. MATERIALS AND EQUIPMENT:

5.1 Reagent:

5.1.1 Refer to DimensionEXL200 ,Synchron DXC700 and Atelica CI CPK reagent leaflet

5.1.2 Analytical Range: serum/plasma 7-1000 U/L

5.1.3 Regents retention:

5.1.3.1 The unopened reagents are stable until the expiration date when stored at 2-8°C. Reagent stability in instrument is 30 days if the reagent is unopened and 5 days for opened well.

5.2 Calibration Process:

5.2.1 Calibration:

5.2.1.1 A complete change of reagents that affects the range used to report patient results or QC value.

5.2.1.2 A reagent kit with new lot number is used .

5.2.1.3 A new assay file that requires a calibration is installed.

5.2.1.4 QC fails to meet the established criteria.

5.2.1.5 After major maintenance or service.

5.2.1.6 When recommended by the manufacturer.

5.2.1.7 Documentation accompanying a new version of an existing file states calibration is required.

5.2.1.8 At least every 6 months.

- 5.2.2 Calibrator retention:
 - 5.2.2.1 At 2-8 C for 24 h. Instability or deterioration should be suspected if there are visible signs of leakage, extreme turbidity microbial growth or if calibration does not meet the appropriate package insert and/or instrument operation manual criteria.
- 5.2.3 Calibration Procedure:
 - 5.2.3.1 Verify that the correct calibrator values have been entered into the calibration file. For details refer to Operator Guide of DimensionEXL200.
 - 5.2.3.2 Allow calibrator to come to room temperature.
 - 5.2.3.3 Mix bottle 10 times by inversion.
 - 5.2.3.4 Open the bottle, place a minimum of 300 ul of each level in separate sample cup, and place on the assigned positions.
 - 5.2.3.5 Cap the bottle tightly and store at 2-8°C. Immediately after use.
 - 5.2.3.6 Perform calibration as indicated in Operator Guide of DimensionEXL200 and SynchronDXC600.
- 5.2.4 Calibration Expected Values:
 - 5.2.4.1 Refer to CPK calibrator for Dimension
 - 5.2.4.2 Refer to ,Synchron DXC700 and Atelica CI calibrator leaflet
- 5.3 **Quality control:**
 - 5.3.1 Normal and pathological control. one time in 24 hours. If more frequent control monitoring is required, the established quality control procedures is followed If quality control results do not fall within an acceptable range defined by laboratory, patient be affected and corrective action should be taken.
 - 5.3.2 Quality Control retention:
 - 5.3.2.1 Unopened control vial is stable up to expiry date printed on the label when stored at cold room.
 - 5.3.2.2 Opened control vial for all analytes will be stable for 4 days at 2 — 8 °C, all analytes will be stable for 30 days at -10 to -20 °C.
 - 5.3.2.3 Instability or deterioration should be suspected if there are visible signs of leakage, extreme microbial growth or if calibration does not meet the appropriate package insert and/or instrument operation manual criteria
 - 5.3.3 QC Procedure:

Verify that the correct QC values have been entered into the QC file. For details refer to Operator Guide of DimensionEXL200 ,Synchron DXC700 and Atelica CI machines.

 - 5.3.3.1 Allow QC to come to room temperature.
 - 5.3.3.2 Gently remove the stopper to avoid loss of the lyophilized pellet and add exactly 5.0 ml distilled or de-ionized water.
 - 5.3.3.3 Leave to stand for 20 minutes
 - 5.3.3.4 Mix bottle several times by inversion to allow homogeneity.
 - 5.3.3.5 Gently invert just prior to use. Avoid foaming.
 - 5.3.3.6 Open bottle, place a minimum of 1000 ul of each level in separate sample cup, and place on the assigned positions.
 - 5.3.3.7 Cap bottle tightly and store at 2-8°C. Immediately after use.
 - 5.3.3.8 Perform QC as indicated in Operator Guide of DimensionEXL200 ,Synchron DXC700 and Atelica CI machines
 - 5.3.4 QC Expected Values:
 - 5.3.4.1 Refer to the Bio-Rad Lyphochek assayed chemistry controls value sheet for DimensionEXL200 ,Synchron DXC700 and Atelica CI machines.

6. RESPONSIBILITIES:

- 6.1 Chemistry shift in charge is responsible for, running calibration and control and samples of Creatine Kinase.
- 6.2 Chemistry staff are responsible for running Creatine Kinase samples all over the day.







7. APPENDICES:

- 7.1 NA

8. REFERENCES:

- 8.1 Tietz Text Book of clinical chemistry and molecular diagnostics 4th Edition, 2006
- 8.2 Company Leaflets of reagents

9. APPROVALS:

| | Name | Title | Signature | Date |
|--------------|-------------------------------|------------------------------------|--|------------------|
| Prepared by: | Dr. Talal Abdelgawad | Clinical Pathologist |  | January 06, 2025 |
| Reviewed by: | Dr. Kawther M. Abdou | Consultant & Lab. Medical Director |  | January 13, 2025 |
| Reviewed by: | Ms. Noora Melfi Alanizi | Laboratory & Blood Bank Director |  | January 13, 2025 |
| Reviewed by: | Mr. Abdulelah Ayed Al Mutairi | QM&PS Director |  | January 13, 2025 |
| Reviewed by: | Dr. Tamer Mohamed Naguib | Medical Director |  | January 13, 2025 |
| Approved by: | Mr. Fahad Hazam Alshammari | Hospital Director |  | January 20, 2025 |